These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7578657

  • 1. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
    Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR.
    Biol Psychiatry; 1995 Aug 01; 38(3):138-49. PubMed ID: 7578657
    [Abstract] [Full Text] [Related]

  • 2. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS, Westenberg HG.
    J Psychiatr Res; 2008 Sep 01; 42(11):894-901. PubMed ID: 18533183
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.
    Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML.
    Pharmacopsychiatry; 2004 Jul 01; 37(4):180-8. PubMed ID: 15467976
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S, John JP, Reddy LP.
    Psychoneuroendocrinology; 2001 Feb 01; 26(2):209-23. PubMed ID: 11087965
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
    Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR.
    Psychiatry Res; 1991 Jan 01; 36(1):1-17. PubMed ID: 2017519
    [Abstract] [Full Text] [Related]

  • 9. Low versus standard dose mCPP challenge in obsessive-compulsive patients.
    Erzegovesi S, Martucci L, Henin M, Bellodi L.
    Neuropsychopharmacology; 2001 Jan 01; 24(1):31-6. PubMed ID: 11106873
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Validation of a scale for responsibility (Salkovskis Responsibility Scale)].
    Bouvard M, Robbe-Grillet P, Milliery M, Pham S, Amireche S, Fanget F, Guerin J, Cottraux J.
    Encephale; 2001 Jan 01; 27(3):229-37. PubMed ID: 11488253
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR.
    Arch Gen Psychiatry; 1988 Feb 01; 45(2):177-85. PubMed ID: 3337615
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Empathy and symptoms dimensions of patients with obsessive-compulsive disorder.
    Fontenelle LF, Soares ID, Miele F, Borges MC, Prazeres AM, Rangé BP, Moll J.
    J Psychiatr Res; 2009 Jan 01; 43(4):455-63. PubMed ID: 18614180
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
    Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL.
    Arch Gen Psychiatry; 1987 Nov 01; 44(11):946-51. PubMed ID: 3675134
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.